Overall benefits of ready-to-administer systems outweigh the initial cost disadvantages, says BD expert
Pre-fillable syringes for intravenous drugs can replace traditional glass vials and ampoules, particularly in the time-sensitive and fast-paced world of emergency care
Ready-to-administer-systems such as pre-fillable syringes can provide benefits to numerous stakeholders including reduction in medication errors, risk of contamination and nurse saving time.
This was the main thrust of Wednesday’s CPHI Discover webinar, Vial to Ready-To-Administer Need and BD solution offerings in acute care, sponsored by BD Medical - Pharmaceutical Systems.
“The only disadvantage is that the cost of a drug-pre-fillable device combination are much higher than that of a drug in a vial or ampoule,” said Sagar Bejalwar, Senior Manager, Global Acute and Specialty Portfolio Marketing at BD Medical - Pharmaceutical Systems.
“There are quite a few benefits that have been documented: the primary benefits are a reduction in medication errors, the reduced risk of contamination, as well as nurse time saving and a reduction in wastage,” he said.
He pinpointed savings in labour time and accurate dosing as critical factors, given that the coronavirus pandemic has reinforced the need for healthcare systems – particularly critical care -- to be much more efficient.
“Ready-to-administer systems do play a part in bringing about that efficiency at least on the point of care,” Bejalwar said, adding that they have the most impact in systems of critical care, which are relatively fast-paced and where there is very little room for error during the medication process.
He said only around 70% of injectable biologic chronic treatments of 50mL or less are packaged in ready-to-administer formats, with only 50% of vaccines available in this format. However, for acute liquid injectable small molecule drugs, the penetration was much less with only 2% are in ready-to-administer format, he added.
As well as the efficiency and time saving benefits to hospital administrator, Bejalwar said prefilled syringes also presented benefits to pharmaceutical players.
“Pharma companies having a generic drug launched in a ready-to-administer system or a prefilled syringe does provide a competitive edge and an opportunity to differentiate in the market that may be dominated by vials and ampoules,” he said.
Bejalwar said BD had recently launched its BD Hylok glass pre-fillable syringe for intravenous drugs primarily in response to malfunction issues with certain types of pin-activated needleless access devices which essentially led to breakage of the tip of the syringes and ultimately disruption to workflows.
“This really did highlight the aspect of incompatibility of pre-fillable syringes with certain designs of needleless access devices and this was specifically highlighted in emergency care settings,” he said.
Bejalwar said that BD’s objective is to position BD Hylok as a solution that meets market needs: “Many pharma companies conduct steam sterilization prior to launching their drug-device combination, and therefore we’ve tested BD Hylok for steam sterilization with water-for-injection to ensure that the pharma companies have that data at hand and are sufficiently equipped to conduct their respective testing processes.”
This webinar will be available on demand from 31 May. In the meantime, for details on how to register for this ongoing virtual event, head to the CPHI Discover website
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance